The State Key Lab of Reproductive, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
The First Clinical Medical College, Nanjing Medical University, Nanjing 211166, P.R. China.
Aging (Albany NY). 2020 Nov 24;12(24):25878-25894. doi: 10.18632/aging.202153.
Extensive research has revealed the pivotal role of kinesin family member 20A (KIF20A) in cancer. However, its latent involvement in renal clear cell carcinoma (ccRCC) still remains unclear. Thus, here we explored the role of KIF20A in ccRCC. For this, a series of software including R (v. 3.6.1), SPSS (v. 23), ImageJ and FlowJo were used for the analyses. Open-access data were obtained from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and Gene Expression Omnibus (GEO) databases. Weighted Gene Co-expression Network Analysis (WGCNA) was used for module gene identification. In vitro results indicated that KIF20A expression is up-regulated in ccRCC tissue. KIF20A knockdown was able to inhibite cell proliferation and invasion of kidney A498 and Caki-1 cells. Meanwhile, KIF20A showed a strong association with immune infiltration. Particularly, KIF20A had a strong positive correlation with Th2 cells, Treg cells and Macrophages, but a negative correlation with Th17 cells, Mast cells and NK cells. These correlations may suggest the use of KIF20A as an underlying immunotherapy target in ccRCC. Our data indicated that KIF20A may promote cell invasion and proliferation in ccRCC, thus serving as an independent tumor marker and a putative therapeutic target.
大量研究揭示了驱动蛋白家族成员 20A(KIF20A)在癌症中的关键作用。然而,其在肾透明细胞癌(ccRCC)中的潜在作用尚不清楚。因此,我们在这里探讨了 KIF20A 在 ccRCC 中的作用。为此,我们使用了一系列软件,包括 R(v.3.6.1)、SPSS(v.23)、ImageJ 和 FlowJo 进行分析。我们从癌症基因组图谱(TCGA)、国际癌症基因组联盟(ICGC)和基因表达综合数据库(GEO)中获取了公开数据。加权基因共表达网络分析(WGCNA)用于模块基因鉴定。体外结果表明,KIF20A 在 ccRCC 组织中表达上调。KIF20A 敲低能够抑制肾 A498 和 Caki-1 细胞的增殖和侵袭。同时,KIF20A 与免疫浸润有很强的相关性。特别是,KIF20A 与 Th2 细胞、Treg 细胞和巨噬细胞呈强正相关,而与 Th17 细胞、肥大细胞和 NK 细胞呈负相关。这些相关性可能表明 KIF20A 可作为 ccRCC 潜在的免疫治疗靶点。我们的数据表明,KIF20A 可能促进 ccRCC 中的细胞侵袭和增殖,因此可作为独立的肿瘤标志物和潜在的治疗靶点。